If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Body Protection Compound 15-mer
Batch documentation
Review BPC-157 identity and batch documentation against your pharmacy QA requirements. Include any PCAC-related review requirements or blend specifications in the inquiry.
Overview
BPC-157 (Body Protection Compound 15-mer) is a 15-amino-acid sequence, GEPPPGKPADDAGLV, derived from a protective fragment originally isolated from human gastric juice. The unusually high proline content of the N-terminal half (four prolines in the first eight residues) kinks the backbone in a way that resists protease access, giving the molecule notable stability in gastric and serum environments and underwriting its use across tendon-ligament, GI mucosal, vascular endothelial, and bone-repair research models. For 503A patient-specific compounders watching the regulatory pipeline: BPC-157 is currently scheduled for FDA PCAC review at the July 2026 meeting against the 503A bulks-list criteria. The procurement and regulatory framing is broken out in two companion articles: our overview of the 503A vs 503B compounding pathways, plus the dedicated BPC-157 procurement playbook for pharmacies. Vialdyne releases BPC-157 acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The 15-residue sequence is reliably accessible by SPPS, but the closely-eluting truncation by-products require disciplined purification, so every released lot comes with its batch COA reporting peak-integration RP-HPLC purity plus ESI-MS confirming the molecular weight inside 0.5 Da of the 1419.55 g/mol theoretical. LC-MS/MS sequence verification with a full b- and y-ion ladder is an available add-on under an agreed pharmacy qualification protocol, ESI-MS alone confirms mass identity, but tandem MS directly proves the synthesised sequence matches the labelled sequence. BPC-157 also feeds the co-lyophilised Wolverine Blend (with TB-500) and the GLOW Blend (with TB-500 and GHK-Cu). For a direct mechanism-and-analytical comparison with TB-500, see the BPC-157 vs TB-500 article.
Applications & buyer fit
Repair peptides, BPC-157, TB-500, and related sequences, typically ship to research labs studying tissue-repair, gastrointestinal, or tendon-ligament models, and to compounding pharmacies that have validated the active material into their workflow. Buyers should request the batch COA for the lot offered or shipped and define any sequence-level evidence required by their written qualification procedure before quotation; Vialdyne does not require buyers to repeat the lot-release tests recorded on the COA.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Start with the applicable batch COA. Add tandem-MS sequence evidence only when the buyer's written procurement procedure requires it and the scope is agreed before quotation.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Nasal spray listing · US inventory
BPC-157 is also listed in this catalog as a nasal spray solution.

Capsule listing
BPC-157 is also listed as a capsule product, dispatched within the United States from US inventory.

Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COABPC-157 2 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COABPC-157 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COABPC-157 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Third-party reportBPC-157 5 mg
HPLC purity · MS identity
Third-party laboratory, Tianjin, China
Full, clear copy from sales
Third-party reportBPC-157 10 mg
HPLC purity · MS identity
Third-party laboratory, Tianjin, China
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Inclusion of BPC-157 on the 503A bulks list is presently before the FDA's PCAC (July 2026). We provide it for research together with commercial use, subject to the buyer's local regulations.
Selected literature
Frequently asked questions
Sequence is GEPPPGKPADDAGLV across 15 residues. The first eight residues alone contain four prolines (PPPGKP segment), and the resulting backbone geometry leaves few cleavage-accessible peptide bonds. The molecule therefore tolerates gastric and serum protease environments far better than typical short peptides, which is the same property that underwrites the published research on oral-route protocols. By contrast, TB-500 is restricted to injectable routes because its longer, more flexible backbone does not survive gastric exposure.
There is no approved finished drug containing BPC-157 in any major jurisdiction at the time of writing. The active is currently scheduled for FDA Pharmacy Compounding Advisory Committee (PCAC) review at the July 2026 meeting, with the proposed indication of ulcerative colitis, under consideration for inclusion on the 503A bulks list. If PCAC's recommendation is accepted by the FDA, 503A pharmacies would gain a clear path to patient-specific compounding using BPC-157. Until that happens, sales are restricted to API use in jurisdictions where local rules permit and to compounding under the receiving pharmacy's own regulatory analysis.
Acetate is the default salt released against the catalogue spec and is the form most pharmacies want, the chromatographic behaviour and reconstitution kinetics are well characterised. Free-base BPC-157 is occasionally requested where a downstream formulator needs to control the final counter-ion themselves. Per-mass biological activity is equivalent across the two; the practical differences are in RP-HPLC retention time (acetate elutes slightly earlier under typical gradient conditions) and in handling pH. Flag salt-form preference at the quote stage so the lot is reserved correctly.
Yes, this is the Wolverine Blend SKU, one of the most-requested co-lyophilised presentations in the catalogue. Co-lyophilisation is operationally preferred over having the receiving pharmacy reconstitute and combine two separate vials, the measured ratio in the cake, rather than the nominal ratio, is available on request and listed on the released-batch COA when tested. Standard fills are 5 + 5 mg (10 mg vial), 10 + 10 mg (20 mg vial), and 15 + 15 mg (30 mg vial); non-standard ratios (10+5, 5+10) can be scoped under a project-specific change-control. Adding GHK-Cu to the blend produces the GLOW Blend SKU, intended for compounding workflows that combine tissue-repair and integumentary endpoints in a single dispense.
Yes. BPC-157 is listed as a nasal spray solution (2 mg, 5 mg, 10 mg), filled in 10 mL or 20 mL bottles, with an MOQ of 10 bottles per content and fill. It is dispatched within the United States from US inventory; send an inquiry for current availability.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides